Products for Research Use Only

DCEBIO

CAT: 0804-HY-102052-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-102052-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia[1][2][3].
CAS Number
60563-36-2
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Potassium Channel
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
COVID-19-immunoregulation
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/dcebio.html
Concentration
10mM
Purity
99.25
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C1NC2=CC(Cl)=C(Cl)C=C2N1CC
Molecular Formula
C9H8Cl2N2O
Molecular Weight
231.08
Precautions
H302, H315, H319, H335
References & Citations
[1]Tanaka S, et al. DCEBIO facilitates myogenic differentiation via intermediate conductance Ca2+ activated K+ channel activation in C2C12 myoblasts. J Pharmacol Sci. 2017 Apr;133 (4) :276-279.|[2]West CL, et al. Identification of SSRI-evoked antidepressant sensory signals by decoding vagus nerve activity. Sci Rep. 2021 Oct 26;11 (1) :21130.|[3]Iseki Y, et al. Opening of Intermediate Conductance Ca2+-Activated K+ Channels in C2C12 Skeletal Muscle Cells Increases the Myotube Diameter via the Akt/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2021 Mar;376 (3) :454-462.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported